NRx Pharmaceuticals receives first commercial manufacturing order for ketamine

NRx Pharmaceuticals (NRXP) announced the initiation of its first commercial manufacturing order of its preservative-free ketamine product in anticipation of approval in Summer 2026. “NRx thanks its manufacturing partner for the care and support that has been invested in this project and looks forward to being able to serve Americans with a safe and convenient US-made ketamine product,” said Jonathan Javitt, chairman and CEO of NRx Pharmaceuticals. The order is based on stability observed in more than three manufactured registration batches and the company’s successful third-party audit of the manufacturing facility. NRx expects the initial manufacturing pace will be sufficient to support initial substantial yearly revenues and notes the ability to rapidly scale manufacturing as demand grows. The product is the first U.S.-manufactured preservative-free ketamine presentation, utilizing a blow-fill-seal process that achieves more than 10-fold higher manufacturing throughput than traditional sterile bottling techniques.